Exane Derivatives Lowers Stake in HCA Holdings, Inc. (HCA)
Exane Derivatives cut its stake in shares of HCA Holdings, Inc. (NYSE:HCA) by 16.7% during the second quarter, Holdings Channel reports. The fund owned 26,094 shares of the company’s stock after selling 5,228 shares during the period. Exane Derivatives’ holdings in HCA Holdings were worth $2,275,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of HCA. IFP Advisors Inc raised its position in HCA Holdings by 9.4% in the first quarter. IFP Advisors Inc now owns 1,605 shares of the company’s stock valued at $143,000 after buying an additional 138 shares during the last quarter. Global X Management Co. LLC raised its position in HCA Holdings by 29.9% in the first quarter. Global X Management Co. LLC now owns 2,162 shares of the company’s stock valued at $192,000 after buying an additional 498 shares during the last quarter. Peak Asset Management LLC acquired a new position in HCA Holdings during the first quarter valued at approximately $201,000. Ifrah Financial Services Inc. acquired a new position in HCA Holdings during the first quarter valued at approximately $210,000. Finally, Checchi Capital Advisers LLC acquired a new position in HCA Holdings during the first quarter valued at approximately $213,000. 74.49% of the stock is owned by institutional investors and hedge funds.
Shares of HCA Holdings, Inc. (NYSE:HCA) traded down 0.16% during trading on Monday, hitting $86.50. 953,491 shares of the stock were exchanged. HCA Holdings, Inc. has a 12-month low of $67.00 and a 12-month high of $91.03. The firm has a 50 day moving average of $83.81 and a 200-day moving average of $82.95. The company has a market cap of $31.74 billion, a price-to-earnings ratio of 11.75 and a beta of 0.68.
HCA Holdings (NYSE:HCA) last released its earnings results on Tuesday, May 2nd. The company reported $1.74 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.74. The company had revenue of $10.62 billion during the quarter, compared to analysts’ expectations of $10.64 billion. HCA Holdings had a negative return on equity of 45.28% and a net margin of 6.70%. The business’s revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.71 EPS. On average, analysts forecast that HCA Holdings, Inc. will post $7.36 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Exane Derivatives Lowers Stake in HCA Holdings, Inc. (HCA)” was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/exane-derivatives-lowers-stake-in-hca-holdings-inc-hca/1446221.html.
Several research analysts have recently commented on HCA shares. Zacks Investment Research raised shares of HCA Holdings from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research note on Thursday. Argus started coverage on shares of HCA Holdings in a research note on Wednesday, June 28th. They issued a “buy” rating and a $100.00 price objective for the company. Cantor Fitzgerald reissued a “buy” rating and issued a $95.00 price objective on shares of HCA Holdings in a research note on Monday, April 17th. Deutsche Bank AG initiated coverage on shares of HCA Holdings in a research note on Tuesday, April 4th. They issued a “buy” rating and a $103.00 price objective for the company. Finally, Mizuho upgraded shares of HCA Holdings from a “neutral” rating to a “buy” rating and set a $98.00 price target for the company in a research note on Monday, March 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the company’s stock. HCA Holdings has an average rating of “Buy” and a consensus price target of $92.71.
In related news, SVP Robert A. Waterman sold 246,000 shares of the firm’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $83.12, for a total transaction of $20,447,520.00. Following the transaction, the senior vice president now directly owns 392,252 shares in the company, valued at $32,603,986.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan B. Perlin sold 71,063 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $86.00, for a total value of $6,111,418.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 395,274 shares of company stock valued at $33,048,964. Company insiders own 2.90% of the company’s stock.
HCA Holdings Company Profile
HCA Healthcare, Inc, formerly HCA Holdings, Inc, is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia.
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Holdings, Inc. (NYSE:HCA).
Receive News & Ratings for HCA Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.